Reproductive disturbances in patients with epilepsy

Martha J. Morrell, MD
College of Physicians and Surgeons, Columbia University, and the Columbia Comprehensive Epilepsy Center, New York–Presbyterian Health System, New York, NY

Georgia D. Montouris, MD
Boston University School of Medicine and the Epilepsy Center of Boston University Medical Center, Boston, MA

Correspondence: Martha J. Morrell, MD, Department of Neurology, The Neurological Institute, 710W. 168th Street, New York, NY 10032

Dr. Morrell receives research support from Novartis, Abbott, the National Institutes of Health, and GlaxoSmithKline; is a consultant for Novartis, Abbott, GlaxoSmithKline, Ortho-McNeil, Elan, and Schwarz Pharma; and has received honoraria from Novartis, Abbott, Pfizer, GlaxoSmithKline, Ortho-McNeil, and Elan.

Dr. Montouris receives grants/research support from Schwarz Pharma and UCB Pharma; is a consultant for Pfizer, GlaxoSmithKline, Abbott, Ortho-McNeil, and Elan; is a stock shareholder (not major) in Johnson & Johnson and Merck; and has received honoraria from Abbott, Cyberonics, Elan, GlaxoSmithKline, Novartis, Ortho-McNeil, UCB Pharma, Shire, Xcel Pharmaceuticals, and Pfizer.

Martha J. Morrell, MD
College of Physicians and Surgeons, Columbia University, and the Columbia Comprehensive Epilepsy Center, New York–Presbyterian Health System, New York, NY

Georgia D. Montouris, MD
Boston University School of Medicine and the Epilepsy Center of Boston University Medical Center, Boston, MA

Correspondence: Martha J. Morrell, MD, Department of Neurology, The Neurological Institute, 710W. 168th Street, New York, NY 10032

Dr. Morrell receives research support from Novartis, Abbott, the National Institutes of Health, and GlaxoSmithKline; is a consultant for Novartis, Abbott, GlaxoSmithKline, Ortho-McNeil, Elan, and Schwarz Pharma; and has received honoraria from Novartis, Abbott, Pfizer, GlaxoSmithKline, Ortho-McNeil, and Elan.

Dr. Montouris receives grants/research support from Schwarz Pharma and UCB Pharma; is a consultant for Pfizer, GlaxoSmithKline, Abbott, Ortho-McNeil, and Elan; is a stock shareholder (not major) in Johnson & Johnson and Merck; and has received honoraria from Abbott, Cyberonics, Elan, GlaxoSmithKline, Novartis, Ortho-McNeil, UCB Pharma, Shire, Xcel Pharmaceuticals, and Pfizer.

Martha J. Morrell, MD
College of Physicians and Surgeons, Columbia University, and the Columbia Comprehensive Epilepsy Center, New York–Presbyterian Health System, New York, NY

Georgia D. Montouris, MD
Boston University School of Medicine and the Epilepsy Center of Boston University Medical Center, Boston, MA

Correspondence: Martha J. Morrell, MD, Department of Neurology, The Neurological Institute, 710W. 168th Street, New York, NY 10032

Dr. Morrell receives research support from Novartis, Abbott, the National Institutes of Health, and GlaxoSmithKline; is a consultant for Novartis, Abbott, GlaxoSmithKline, Ortho-McNeil, Elan, and Schwarz Pharma; and has received honoraria from Novartis, Abbott, Pfizer, GlaxoSmithKline, Ortho-McNeil, and Elan.

Dr. Montouris receives grants/research support from Schwarz Pharma and UCB Pharma; is a consultant for Pfizer, GlaxoSmithKline, Abbott, Ortho-McNeil, and Elan; is a stock shareholder (not major) in Johnson & Johnson and Merck; and has received honoraria from Abbott, Cyberonics, Elan, GlaxoSmithKline, Novartis, Ortho-McNeil, UCB Pharma, Shire, Xcel Pharmaceuticals, and Pfizer.